Last reviewed · How we verify
ABT-493/ABT-530
ABT-493/ABT-530 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication.
ABT-493/ABT-530 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), Hepatitis C in treatment-naïve and treatment-experienced patients, Hepatitis C with compensated cirrhosis.
At a glance
| Generic name | ABT-493/ABT-530 |
|---|---|
| Also known as | ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET, glecaprevir/pibrentasvir, glecaprevir (ABT-493) |
| Sponsor | AbbVie |
| Drug class | Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor) |
| Target | HCV NS3/4A protease and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
ABT-493 (glecaprevir) inhibits the NS3/4A protease, preventing viral polyprotein processing, while ABT-530 (pibrentasvir) inhibits NS5A, a multifunctional protein essential for viral replication and assembly. Together, these direct-acting antivirals target two critical steps in the hepatitis C virus lifecycle, achieving high cure rates across multiple HCV genotypes.
Approved indications
- Chronic hepatitis C virus infection (genotypes 1-6)
- Hepatitis C in treatment-naïve and treatment-experienced patients
- Hepatitis C with compensated cirrhosis
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (PHASE2, PHASE3)
- Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (PHASE3)
- A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (PHASE3)
- A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (PHASE3)
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-493/ABT-530 CI brief — competitive landscape report
- ABT-493/ABT-530 updates RSS · CI watch RSS
- AbbVie portfolio CI